3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Unknown
3
Completed
3
Withdrawn
1
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
9
Breast
6
Gynecologic
3
Thoracic
2
Other hematologic neoplasm
2
Head & Neck
2
Tumor-Agnostic
1
NET
1
Lymphoid
1
Endocrine
1
Dermatologic
1
Classical hematology
1
Conditions
Neoplasms
1
Interventions
pembrolizumab
26
Specimen Handling
17
Blood Specimen Collection
17
Biopsy
16
Magnetic Resonance Spectroscopy
15
atezolizumab
11
Surveys and Questionnaires
11
Bevacizumab
9
Radiotherapy
8
Radiosurgery
8
Nivolumab
8
Fluorouracil
8
Standard of Care
7
Paclitaxel
7
Irinotecan
7
Gemcitabine
7
Cisplatin
7
olaparib
6
durvalumab
6
Palliative Care
6
Oxaliplatin
6
Leucovorin
6
Cyclophosphamide
6
Carboplatin
6
Capecitabine
6
alectinib
5
abemaciclib
5
Trastuzumab
5
Interviews as Topic
5
Exercise
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Control Groups
×
Tumor-Agnostic
×
Clear all
NCT06782581
2025-12-31
CARE
Fox Chase Cancer Center
Phase NA
Recruiting
186 enrolled